Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 6Terminated 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Conditions

Melanoma 49Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Neoplasm Metastasis 10Carcinoma, Renal Cell 7Skin Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Lung Neoplasms 4Glioblastoma 4Diabetes Mellitus, Insulin-Dependent, 12 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Advanced Cancer 4Uveal Melanoma 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Sarcoma 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2

Interventions

Nivolumab 6Ipilimumab 46-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2tilsotolimod 1relatlimab 1mirdametinib 1linrodostat 1gedatolisib 1figitumumab 1Valganciclovir 1Tablets 1Surveys and Questionnaires 1Sunitinib 1Paclitaxel 1LY2584702 1Irinotecan 1EC145 1Dasatinib 1Chlorogenic Acid 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Advanced Cancer × Ipilimumab × Clear all
NCT03110107 2025-04-24

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Terminated
376 enrolled 56 charts

Advanced Cancer

NCT04270864 2024-10-18

PRIMO

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1 Terminated
25 enrolled

Advanced Cancer

NCT03444753 2022-05-23

An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

Bristol-Myers Squibb

Phase 1 Terminated
82 enrolled

Advanced Cancer

NCT02750514 2021-03-22

FRACTION-Lung

Bristol-Myers Squibb

Phase 2 Terminated
295 enrolled 21 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡